A recent analysis of Global Burden of Disease Study 2023 (GBD 2023) estimates reports that in 2023 roughly 88.7% of ischemic heart disease deaths in the United States were attributable to modifiable risk factors. The article summarizes findings that, although total ischemic heart disease deaths have fallen since 1990, specific preventable exposures remain dominant drivers of mortality and some have increased in impact over the last three decades.
The investigators used data from GBD 2023 to assess estimated ischemic heart disease death rates and exposure to risk factors between 1990 and 2023. The study evaluated attribution of deaths to selected modifiable exposures over that period. The summary in the source lists the data source and timeframe but does not provide detailed analytic methods, uncertainty intervals, or granular state-level results in the text provided.
The study examined 12 risk factors across metabolic, behavioral, and environmental domains. Metabolic risks included high LDL cholesterol, high systolic blood pressure, high body mass index (BMI), and high fasting plasma glucose (fasting blood sugar). Behavioral risks included smoking, alcohol consumption, and sedentary lifestyle. Environmental risks included particulate matter pollution and lead exposure. The article emphasizes that many of these risks are modifiable through clinical care, public health measures, and individual behavior change.
According to the report, there were an estimated 473,000 ischemic heart disease deaths in the United States in 2023. That total represents a 58.7% decrease from the number of ischemic heart disease deaths reported in 1990. Despite this long-term decline in overall mortality, the proportion of deaths attributable to modifiable risk factors remains high, and the relative contributions of specific risks have shifted over time.
In 2023 the leading modifiable contributors to ischemic heart disease mortality in the U.S. were high systolic blood pressure (accountable for 47.2% of ischemic heart disease deaths), dietary risks (38.6%), and high LDL cholesterol (28.5%). The article highlights that many of these major contributors are conditions that frequently cause no symptoms, reinforcing the need for screening and management.
Among the 12 risk factors analyzed, deaths attributable to high BMI and high fasting plasma glucose showed the largest increases since 1990, rising by 12.5% and 10.5%, respectively. Study authors and interviewed clinicians described these trends as concerning, noting that obesity-related conditions and diabetes are becoming stronger contributors to ischemic heart disease burden while other risks, such as smoking, have declined in relative contribution.
The article quotes Gregory Roth, MD, MPH, lead author and director of the Program in Cardiovascular Health Metrics, who emphasized that tracking modifiable risks is essential and that progress has been insufficient. Clinicians interviewed—Carlos Alfonso, MD, and Cheng-Han Chen, MD—echoed the findings, observing clinical trends of decreasing smoking-related risk but increasing influence from obesity and diabetes. They reiterated that ischemic heart disease remains the leading cause of mortality in the U.S. and that combined population- and individual-level strategies are needed.
Experts cited in the article recommend several approaches that clinicians can reinforce with patients:
The article frames these steps as achievable at both individual and system levels, and emphasizes that prevention could substantially reduce premature ischemic heart disease deaths.
The source article summarizes key findings from the GBD-based study but does not include several methodological details. The summary does not report confidence intervals or uncertainty estimates, specific analytic methods, full state-by-state comparisons, or exact population denominators beyond the cited 473,000 U.S. deaths in 2023 and the 58.7% decline since 1990. Where such details are not reported in the source, they are not asserted here.
Overall, the article underscores that most U.S. ischemic heart disease deaths in 2023 were linked to modifiable risk factors, with high systolic blood pressure, poor diet, and high LDL cholesterol leading, while rising obesity and fasting glucose now represent accelerating threats that require intensified prevention and treatment efforts.